<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04492423</url>
  </required_header>
  <id_info>
    <org_study_id>VFN-CSS-16-0003</org_study_id>
    <nct_id>NCT04492423</nct_id>
  </id_info>
  <brief_title>VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study</brief_title>
  <official_title>VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accriva Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Accriva Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the range of expected PRUTest values in patients in&#xD;
      the intended use population receiving dual antiplatelet treatment with aspirin and prasugrel&#xD;
      (Effient®), or ticagrelor (Brilinta®).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The on-drug reference range study will be performed by measuring venous blood samples in&#xD;
      duplicate collected from patients receiving prasugrel (Effient®), or ticagrelor (Brilinta®).&#xD;
      Subjects must be on aspirin at the doses prescribed by their treating physician.&#xD;
&#xD;
      When possible, venous blood samples may be collected in conjunction with routine laboratory&#xD;
      testing, to minimize the number of needle sticks for the subject. Alternatively, samples may&#xD;
      be collected separately to complete the study.&#xD;
&#xD;
      A CBC measurement must be performed for each enrolled subject from a sample collected at the&#xD;
      time of blood draw or within ± one week and tested at a certified laboratory. Samples for&#xD;
      PRUTest collected in conjunction with a CBC must be drawn after the PRUTest sample.&#xD;
&#xD;
      Up to 130 subjects will be enrolled in the study to facilitate collection of the minimum&#xD;
      number of blood samples needed to determine the on-drug reference range of prasugrel&#xD;
      (Effient®), or ticagrelor (Brilinta®).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 6, 2016</start_date>
  <completion_date type="Actual">March 22, 2018</completion_date>
  <primary_completion_date type="Actual">August 14, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PRUTest</measure>
    <time_frame>Within 24 hours of the loading or last maintance dose</time_frame>
    <description>VerifyNow PRUTest results</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Platelet Aggregation</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <description>Patients taking prasugrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <description>Patients taking ticagrelor</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>VerifyNow PRUTest</intervention_name>
    <description>VerifyNow PRUTest for platelet aggregation</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Up to 130 subjects will be enrolled in the study to facilitate collection of the minimum&#xD;
        number of blood samples needed to determine the on-drug reference range of prasugrel&#xD;
        (Effient®), or ticagrelor (Brilinta®).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Males and females 18 years and older&#xD;
&#xD;
               -  Able and willing to provide written informed consent.&#xD;
&#xD;
               -  Current treatment with aspirin (any dose).&#xD;
&#xD;
               -  Have a planned or scheduled percutaneous coronary intervention (PCI) with the&#xD;
                  potential to receive treatment with prasugrel (Effient®), or ticagrelor&#xD;
                  (Brilinta®) following an oral loading dose or on maintenance treatment for a&#xD;
                  minimum of seven days who may have symptomatic cerebrovascular disease (transient&#xD;
                  ischemic attack or following a thrombotic stroke) or cardiovascular disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Unable to provide written informed consent.&#xD;
&#xD;
               -  Currently receiving an investigational antiplatelet agent.&#xD;
&#xD;
               -  GP IIb/IIIa therapy (ReoPro®, Integrilin®, Aggrastat®) within the past 2 weeks.&#xD;
&#xD;
               -  Received any therapy containing dipyridamole (Persantine®, Aggrenox®) within the&#xD;
                  past 2 weeks.&#xD;
&#xD;
               -  Women who may be pregnant or are of child bearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominick J Angiolillo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uunversity of Florida Health Jacksonville</affiliation>
  </overall_official>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aggregation</keyword>
  <keyword>platelet</keyword>
  <keyword>P2Y12 inhibitor</keyword>
  <keyword>Aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Publication of Results</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

